KRAS and lung cancer: Kim E.Y. et al. (2017) found that MRS was frequently overexpressed in cancer tissues from LSL-Kras G12D and LSL-Kras G12D:p53fl/fl mice and human lung cancer tissues. Importantly, MRS could regulate the activity of mTORC1 signaling, and its overexpression was associated with poor prognosis in NSCLC, suggesting that MRS might contribute to the development of lung cancer (Kim E.Y. et al., 2017). Furthermore, the levels of nuclear KRS were significantly predictive of disease-free survival in NSCLC patients (Boulos et al., 2017).